Insmed Inc (INSM)vsZentalis Pharmaceuticals Llc (ZNTL)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
ZNTL
Zentalis Pharmaceuticals Llc
$2.55
+3.24%
HEALTHCARE · Cap: $159.93M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 2157% more annual revenue ($606.42M vs $26.86M). ZNTL leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
ZNTL
Avoid32
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : ZNTL
The strongest argument for ZNTL centers on Price/Book, Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : ZNTL
The primary concerns for ZNTL are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while ZNTL is a value play — different risk/reward profiles.
ZNTL carries more volatility with a beta of 1.71 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ZNTL generates stronger free cash flow (-27M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Zentalis Pharmaceuticals Llc
HEALTHCARE · BIOTECHNOLOGY · USA
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?